DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Escudier B. et al.
Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology.
Eur J Cancer 2016;
69: 226-235
Access:
We do not assume any responsibility for the contents of the web pages of other providers.